Scott Hutton - 23 Feb 2021 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
President & CEO, Director
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Scott Hutton
Issuer symbol
BDSX
Transactions as of
23 Feb 2021
Net transactions value
$0
Form type
4
Filing time
26 Jul 2023, 18:05:07 UTC
Next filing
18 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Stock Options (Right to buy) Award $0 +255,688 $0.000000 255,688 23 Feb 2021 Common Stock 255,688 $20.67 Direct F1
transaction BDSX Stock Options (Right to buy) Award $0 +115,203 $0.000000 115,203 23 Feb 2021 Common Stock 115,203 $20.67 Direct F2
transaction BDSX Stock Options (Right to buy) Disposed to Issuer -255,688 -100% 0 24 Jul 2023 Common Stock 255,688 $20.67 Direct F1, F3, F4
transaction BDSX Stock Options (Right to buy) Disposed to Issuer -115,203 -100% 0 24 Jul 2023 Common Stock 115,203 $20.67 Direct F2, F3, F4
transaction BDSX Stock Options (Right to buy) Award +75,693 75,693 24 Jul 2023 Common Stock 75,693 $1.20 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.
F2 This option was fully vested as of the grant date.
F3 On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.
F4 The Reporting Person elected to participate in the Tender Offer and received 75,693 Replacement Options with an exercise price of $1.20 per share in exchange for 370,891 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.
F5 This Replacement Option vests as follows: 48,733 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 26,960 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.